Figure 3. Non-relapse mortality and relapse incidence in patients receiving a myeloablative regimen with selected busulfan doses.

The cumulative incidence of relapse and non-relapse mortality by conditioning regimen (TBF with busulfan 9.6 mg/kg vs BF with busulfan 12.8 mg/kg).